BioSpace News Archive

Doubling down on efforts to prepare highly qualified young scientists for a career in immune disease-focused medical research, The Feinstein Institutes for Medical Research, the science arm of Northwell Health, has been awarded a multi-year National Institutes for Health grant totaling $1.5 million.

Aleta Biotherapeutics, a privately held immuno-oncology company focused on transforming cellular therapeutics to allow a broad spectrum of cancer indications to be targeted, today announced a poster presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting, to be held in Washington, D.C. and in a virtual platform on November 10-14, 2021.

Patients taking mirikizumab for their moderately to severely active ulcerative colitis (UC), were in symptomatic remission for up to two years as demonstrated in new results from Eli Lilly and Company’s (NYSE: LLY) Phase 2 study.

Vertice Pharma announces the results of a recent study demonstrating the bioequivalence of Thyquidity™, an oral liquid solution of levothyroxine sodium to Synthroid®.

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (“Actinium” or the “Company”), today announced that two abstracts featuring targeted radiotherapies in combination with CD47 antibody immunotherapy for solid tumor and hematologic indications have been accepted for presentation at the 36th Annual Meeting of the Society for Immunotherapy for Cancer (SITC 2021).

The Food and Drug Administration’s Office of Counterterrorism and Emerging Threats has awarded a contract worth over $1.78M to Siemens Government Technologies with technology from Siemens Digital Industries.

Schweiger Dermatology Group, the fastest-growing dermatology practice in the Northeast, has announced the acquisition of the Warmuth Institute of Dermatology, with offices in Elmer and Swedesboro, New Jersey.

The Texas Heart Institute has announced that a research team led by its Vice President for Research has pinpointed a game-changing application for the 7HP349 integrin activator

Today, the U.S. Food and Drug Administration is announcing two upcoming meetings of its Vaccines and Related Biological Products Advisory Committee (VRBPAC) to discuss newly available data for the currently available COVID-19 vaccines.

Macomics Ltd, an immuno-oncology company with world-leading expertise in macrophage biology, announces today that it has made five new appointments to its scientific team, to support and accelerate its R&D.